AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer
Adding bevacizumab to single-agent chemotherapy doubled the time to progression and the response rate in platinum-resistant ovarian cancer, becoming the first regimen to improve outcomes in this hard-to-treat setting.
Overview
Phase 3 trial of 361 patients with platinum-resistant ovarian cancer (progression within six months of platinum) and up to two prior regimens randomised to weekly paclitaxel, pegylated liposomal doxorubicin or topotecan with or without bevacizumab.
Median progression-free survival was 6.7 versus 3.4 months (hazard ratio 0.48) and objective response 27.3 versus 11.8 percent; overall survival was not significantly improved (16.6 versus 13.3 months), partly because of crossover.
- Median progression-free survival 6.7 vs 3.4 months; hazard ratio 0.48.
- Objective response 27.3 percent vs 11.8 percent.
Bevacizumab with weekly paclitaxel or other single agents is a standard for platinum-resistant ovarian cancer in bevacizumab-naive patients, and the control regimen for later trials such as MIRASOL and ROSELLA.
- No significant overall survival benefit.
- Patients with bowel involvement were excluded because of perforation risk.
Similar pages
not linked directly; found by shared links- TrialA Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
- TrialA Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
- TrialInvestigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- TrialKEYNOTE-B96 / ENGOT-ov65